Singapore Markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
12.66+0.86 (+7.29%)
At close: 4:00PM EDT

12.47 -0.19 (-1.50%)
Before hours: 7:20AM EDT

Full screen
Trade prices are not sourced from all markets
Previous close11.80
Open12.51
Bid12.43 x 3200
Ask12.47 x 1800
Day's range12.01 - 12.74
52-week range6.07 - 13.76
Volume20,420,565
Avg. volume10,124,135
Market cap13.68B
Beta (5Y monthly)N/A
PE ratio (TTM)3,165.00
EPS (TTM)0.00
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est11.64
  • Teva (TEVA) Q2 Earnings Beat, Sales Miss, Keeps 2020 View
    Zacks

    Teva (TEVA) Q2 Earnings Beat, Sales Miss, Keeps 2020 View

    Teva beats estimates for earnings while missing the same for sales in second-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.

  • Teva Pharm second-quarter profit tops forecast, reaffirms 2020 outlook
    Reuters

    Teva Pharm second-quarter profit tops forecast, reaffirms 2020 outlook

    Teva Pharmaceutical Industries' <TEVA.TA> quarterly profit beat estimates by two cents and the company reaffirmed its outlook for 2020 despite uncertainty generated by the COVID-19 crisis. The company also released with Regeneron Pharmaceuticals <REGN.O> results for advanced trials for pain medication fasinumab. Teva CEO Kare Schultz said the companies were still waiting for more safety data.

  • Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market
    Business Wire

    Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

    Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates. This strategic partnership combines Teva’s long-standing commercial presence and extensive infrastructure in the U.S. market with Alvotech’s scientific experience and state-of-the-art biologics manufacturing. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.